IFNA1 and COVID-19: The WHO’s Solidarity trial was the first major study to show the limited clinical effectiveness, in terms of mortality, of three repurposed antivirals in hospitalized COVID-19 patients: lopinavir, hydroxychloroquine, and interferon (IFN)-β1a.